Edwards Lifesciences Corp (EW) - Total Liabilities
Based on the latest financial reports, Edwards Lifesciences Corp (EW) has total liabilities worth $3.07 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Edwards Lifesciences Corp cash conversion from operations to assess how effectively this company generates cash.
Edwards Lifesciences Corp - Total Liabilities Trend (1999–2024)
This chart illustrates how Edwards Lifesciences Corp's total liabilities have evolved over time, based on quarterly financial data. Check Edwards Lifesciences Corp (EW) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Edwards Lifesciences Corp Competitors by Total Liabilities
The table below lists competitors of Edwards Lifesciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Compagnie de Saint-Gobain S.A.
PA:SGO
|
France | €36.18 Billion |
|
Carvana Co
NYSE:CVNA
|
USA | $9.00 Billion |
|
Woodside Energy Group Ltd
AU:WDS
|
Australia | AU$26.68 Billion |
|
MicroStrategy Incorporated
NASDAQ:MSTR
|
USA | $10.60 Billion |
|
Banco Bradesco DRC
BA:BBD
|
Argentina | AR$2.03 Trillion |
|
Ambev S.A.
SA:ABEV3
|
Brazil | R$57.17 Billion |
|
Banco Santander Brasil SA ADR
NYSE:BSBR
|
USA | $1.14 Trillion |
Liability Composition Analysis (1999–2024)
This chart breaks down Edwards Lifesciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EW market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.69 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Edwards Lifesciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Edwards Lifesciences Corp (1999–2024)
The table below shows the annual total liabilities of Edwards Lifesciences Corp from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.99 Billion | +13.19% |
| 2023-12-31 | $2.64 Billion | +6.36% |
| 2022-12-31 | $2.49 Billion | -6.78% |
| 2021-12-31 | $2.67 Billion | +0.15% |
| 2020-12-31 | $2.66 Billion | +13.80% |
| 2019-12-31 | $2.34 Billion | +7.17% |
| 2018-12-31 | $2.18 Billion | -19.19% |
| 2017-12-31 | $2.70 Billion | +42.88% |
| 2016-12-31 | $1.89 Billion | +21.51% |
| 2015-12-31 | $1.56 Billion | +16.75% |
| 2014-12-31 | $1.33 Billion | +14.36% |
| 2013-12-31 | $1.17 Billion | +57.03% |
| 2012-12-31 | $742.20 Million | +15.50% |
| 2011-12-31 | $642.60 Million | +40.00% |
| 2010-12-31 | $459.00 Million | +0.31% |
| 2009-12-31 | $457.60 Million | -12.24% |
| 2008-12-31 | $521.40 Million | +2.22% |
| 2007-12-31 | $510.10 Million | +2.55% |
| 2006-12-31 | $497.40 Million | -7.74% |
| 2005-12-31 | $539.10 Million | +11.25% |
| 2004-12-31 | $484.60 Million | +3.92% |
| 2003-12-31 | $466.30 Million | -0.53% |
| 2002-12-31 | $468.80 Million | -8.79% |
| 2001-12-31 | $514.00 Million | -20.68% |
| 2000-12-31 | $648.00 Million | +204.23% |
| 1999-12-31 | $213.00 Million | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement prod… Read more